Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction

William E. Boden, Seth Baum, Peter P. Toth, Sergio Fazio, Deepak L. Bhatt

    Research output: Contribution to journalReview articlepeer-review

    3 Scopus citations

    Abstract

    Hypertriglyceridemia is associated with increased cardiovascular disease (CVD) risk. The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) demonstrated that the purified, stable ethyl ester of eicosapentaenoic acid, icosapent ethyl (IPE), added to statins reduced CVD events by 25% (p < 0.001), leading to an expanded indication in the USA. IPE is now approved as an adjunct to maximally tolerated statins to reduce CVD event risk in adults with triglyceride (TG) levels ≥150 mg/dl and either established CVD or diabetes mellitus plus ≥2 additional CVD risk factors. The new indication allows co-administration of IPE for elevated TG levels with statin treatment, enabling effective residual risk reduction in a broader at-risk population beyond what can be achieved with intensive low-density lipoprotein cholesterol control alone.

    Original languageEnglish (US)
    Pages (from-to)155-174
    Number of pages20
    JournalFuture Cardiology
    Volume17
    Issue number1
    DOIs
    StatePublished - Jan 2021

    Keywords

    • cardiovascular disease
    • eicosapentaenoic acid
    • heart diseases
    • hypertriglyceridemia
    • icosapent ethyl
    • triglycerides

    ASJC Scopus subject areas

    • Molecular Medicine
    • Cardiology and Cardiovascular Medicine

    Fingerprint

    Dive into the research topics of 'Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction'. Together they form a unique fingerprint.

    Cite this